Drug Profile
Fenofibrate - Samyang
Alternative Names: SYO-0805Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation; Samyang Group
- Developer Samyang Biopharmaceuticals Corporation
- Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO)
- 31 Aug 2011 Samyang completes a phase I trial in Healthy volunteers in South Korea (NCT01353404)